Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Pieris Pharmaceuticals stock | $2.93

Own Pieris Pharmaceuticals stock in just a few minutes.


Fact checked

Pieris Pharmaceuticals, Inc is a biotechnology business based in the US. Pieris Pharmaceuticals shares (PIRS) are listed on the NASDAQ and all prices are listed in US Dollars. Pieris Pharmaceuticals employs 114 staff and has a trailing 12-month revenue of around USD$44.7 million.

How to buy shares in Pieris Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Pieris Pharmaceuticals. Find the stock by name or ticker symbol: PIRS. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Pieris Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$2.93, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Pieris Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Pieris Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Pieris Pharmaceuticals share price

Use our graph to track the performance of PIRS stocks over time.

Pieris Pharmaceuticals shares at a glance

Information last updated 2020-11-30.
Latest market closeUSD$2.93
52-week rangeUSD$1.6 - USD$4.3
50-day moving average USD$2.57
200-day moving average USD$2.8232
Wall St. target priceUSD$7.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.767

Buy Pieris Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Pieris Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Pieris Pharmaceuticals price performance over time

Historical closes compared with the close of $2.93 from 2020-12-09

1 week (2021-01-09) N/A
1 month (2020-12-16) 0.34%
3 months (2020-10-20) 25.75%
6 months (2020-07-16) N/A
1 year (2020-01-16) N/A
2 years (2019-01-16) N/A
3 years (2018-01-16) N/A
5 years (2016-01-16) N/A

Pieris Pharmaceuticals financials

Revenue TTM USD$44.7 million
Gross profit TTM USD$46.3 million
Return on assets TTM -12.28%
Return on equity TTM -73.37%
Profit margin -52.78%
Book value $0.781
Market capitalisation USD$158.4 million

TTM: trailing 12 months

Shorting Pieris Pharmaceuticals shares

There are currently 2.0 million Pieris Pharmaceuticals shares held short by investors – that's known as Pieris Pharmaceuticals's "short interest". This figure is 7.9% down from 2.2 million last month.

There are a few different ways that this level of interest in shorting Pieris Pharmaceuticals shares can be evaluated.

Pieris Pharmaceuticals's "short interest ratio" (SIR)

Pieris Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Pieris Pharmaceuticals shares currently shorted divided by the average quantity of Pieris Pharmaceuticals shares traded daily (recently around 377582.8358209). Pieris Pharmaceuticals's SIR currently stands at 5.36. In other words for every 100,000 Pieris Pharmaceuticals shares traded daily on the market, roughly 5360 shares are currently held short.

However Pieris Pharmaceuticals's short interest can also be evaluated against the total number of Pieris Pharmaceuticals shares, or, against the total number of tradable Pieris Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Pieris Pharmaceuticals's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Pieris Pharmaceuticals shares in existence, roughly 40 shares are currently held short) or 0.0397% of the tradable shares (for every 100,000 tradable Pieris Pharmaceuticals shares, roughly 40 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Pieris Pharmaceuticals.

Find out more about how you can short Pieris Pharmaceuticals stock.

Pieris Pharmaceuticals share dividends

We're not expecting Pieris Pharmaceuticals to pay a dividend over the next 12 months.

Have Pieris Pharmaceuticals's shares ever split?

Pieris Pharmaceuticals's shares were split on a 2:1 basis on 8 December 2014. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Pieris Pharmaceuticals shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Pieris Pharmaceuticals shares which in turn could have impacted Pieris Pharmaceuticals's share price.

Pieris Pharmaceuticals share price volatility

Over the last 12 months, Pieris Pharmaceuticals's shares have ranged in value from as little as $1.6 up to $4.3. A popular way to gauge a stock's volatility is its "beta".

PIRS.US volatility(beta: 1.45)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Pieris Pharmaceuticals's is 1.4549. This would suggest that Pieris Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Pieris Pharmaceuticals overview

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. Its lead respiratory program includes PRS-060, a drug candidate, which is in Phase I clinical trial that binds to IL-4Ra for the treatment of asthma and other inflammatory diseases; and lead immuno-oncology program comprises PRS-343, a bispecific protein that is in Phase I clinical trial for oncology diseases. The company also develops PRS-344, a bispecific anticalin-antibody fusion protein that is in preclinical stage for oncology diseases; and PRS-080, a polyethylene glycol conjugated anticalin protein that is in Phase IIa clinical trial to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis, as well as other drugs. It has strategic partnerships with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seattle Genetics Inc.; and license agreements with TUM, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a research collaboration with the laboratories of University of Pittsburgh. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site